MedTrace Logo

Systemic Synuclein Sampling Study (S4)

NCT02572713 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2017-08-17

No results posted yet for this study

Summary

The purpose of this study is to measure alpha-synuclein in peripheral body tissues and fluids in Parkinson's disease (PD). This may help in developing better treatments for PD patients in the future.

Conditions

Interventions

PROCEDURE

Biofluid samplings

Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)

PROCEDURE

Tissue samplings

Tissue samplings (skin, colon, submandibular gland)

DRUG

DaTSCAN™

Sponsors & Collaborators

  • Indiana University

    collaborator OTHER

  • University of Iowa

    collaborator OTHER

  • Banner Health

    collaborator OTHER

  • Paracelsus Elena Klinik

    collaborator OTHER

  • Michael J. Fox Foundation for Parkinson's Research

    lead OTHER

Principal Investigators

  • Lana Chahine, MD · University of Pennsylvania

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-08-01
Completion
2017-08-01

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02572713 on ClinicalTrials.gov